Today's Top Performers In Health Services

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 80 points (0.5%) at 15,453 as of Tuesday, Feb. 4, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 2,024 issues advancing vs. 894 declining with 170 unchanged.

The Health Services industry currently sits up 0.2% versus the S&P 500, which is up 0.7%. Top gainers within the industry include Agilent Technologies ( A), up 1.4%, St Jude Medical ( STJ), up 0.7% and Thermo Fisher Scientific ( TMO), up 0.7%. A company within the industry that fell today was Fresenius Medical Care AG & Co. KGaA ( FMS), up 1.0%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. WuXi PharmaTech (Cayman ( WX) is one of the companies pushing the Health Services industry higher today. As of noon trading, WuXi PharmaTech (Cayman is up $1.58 (4.8%) to $34.16 on average volume. Thus far, 259,492 shares of WuXi PharmaTech (Cayman exchanged hands as compared to its average daily volume of 679,300 shares. The stock has ranged in price between $32.63-$34.16 after having opened the day at $32.63 as compared to the previous trading day's close of $32.58.

Wuxi PharmaTech (Cayman) Inc., through its subsidiaries, operates as a pharmaceutical, biotechnology, and medical device research and development outsourcing company in China and the United States. It operates in two segments, Laboratory Services and Manufacturing Services. WuXi PharmaTech (Cayman has a market cap of $2.5 billion and is part of the health care sector. The company has a P/E ratio of 23.7, above the S&P 500 P/E ratio of 17.7. Shares are down 15.1% year-to-date as of the close of trading on Monday. Currently there are 7 analysts who rate WuXi PharmaTech (Cayman a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates WuXi PharmaTech (Cayman as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full WuXi PharmaTech (Cayman Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

4. As of noon trading, C.R. Bard ( BCR) is up $1.66 (1.3%) to $127.08 on average volume. Thus far, 295,145 shares of C.R. Bard exchanged hands as compared to its average daily volume of 559,400 shares. The stock has ranged in price between $125.48-$127.12 after having opened the day at $126.09 as compared to the previous trading day's close of $125.42.

C. R. Bard, Inc. designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. C.R. Bard has a market cap of $10.1 billion and is part of the health care sector. The company has a P/E ratio of 22.4, above the S&P 500 P/E ratio of 17.7. Shares are down 6.4% year-to-date as of the close of trading on Monday. Currently there are 4 analysts who rate C.R. Bard a buy, 1 analyst rates it a sell, and 10 rate it a hold.

TheStreet Ratings rates C.R. Bard as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, solid stock price performance and impressive record of earnings per share growth. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full C.R. Bard Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

3. As of noon trading, Becton Dickinson ( BDX) is up $0.94 (0.9%) to $106.34 on average volume. Thus far, 572,447 shares of Becton Dickinson exchanged hands as compared to its average daily volume of 793,700 shares. The stock has ranged in price between $106.04-$108.35 after having opened the day at $107.29 as compared to the previous trading day's close of $105.40.

Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. The company's BD Medical segment produces medical devices that are used in various healthcare settings. Becton Dickinson has a market cap of $21.0 billion and is part of the health care sector. The company has a P/E ratio of 23.1, above the S&P 500 P/E ratio of 17.7. Shares are down 4.6% year-to-date as of the close of trading on Monday. Currently there are 6 analysts who rate Becton Dickinson a buy, 3 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Becton Dickinson as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Becton Dickinson Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Edwards Life ( EW) is up $1.14 (1.8%) to $65.31 on heavy volume. Thus far, 1.4 million shares of Edwards Life exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $63.25-$65.49 after having opened the day at $63.91 as compared to the previous trading day's close of $64.17.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. Edwards Life has a market cap of $7.1 billion and is part of the health care sector. The company has a P/E ratio of 18.5, above the S&P 500 P/E ratio of 17.7. Shares are down 2.4% year-to-date as of the close of trading on Monday. Currently there are 6 analysts who rate Edwards Life a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Edwards Life as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth and increase in net income. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full Edwards Life Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Intuitive Surgical ( ISRG) is up $8.49 (2.1%) to $409.66 on average volume. Thus far, 188,824 shares of Intuitive Surgical exchanged hands as compared to its average daily volume of 502,300 shares. The stock has ranged in price between $402.46-$413.96 after having opened the day at $403.31 as compared to the previous trading day's close of $401.17.

Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. Intuitive Surgical has a market cap of $15.5 billion and is part of the health care sector. The company has a P/E ratio of 24.4, above the S&P 500 P/E ratio of 17.7. Shares are up 4.5% year-to-date as of the close of trading on Monday. Currently there are 8 analysts who rate Intuitive Surgical a buy, 4 analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Intuitive Surgical as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, expanding profit margins, growth in earnings per share and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Intuitive Surgical Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Video: The S&P 500 Is Failing to Make New Highs

Video: The S&P 500 Is Failing to Make New Highs

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists